CP alleviates HbA1c level in T2DM patients
fasting blood glucose×, T2DM, fasting blood glucose, post-meal blood glucose
INSULIN RESISTANCE
Compared with Day 0, the level of HbA1c, the primary clinical outcome, was significantly decreased both in the G group and in the CP group on Day 84. At the end of intervention, there was no significant difference in the reduction of HbA1c between the two groups (The changes in glucose metabolism phenotypes in T2DM patients. Comparison of metabolic parameters in T2DM patients.The data are shown as the mean ± SD for normal variables or median (IQR) for non-normal variables. Paired T-test or non-parametric two-tailed Wilcoxon paired sign rank test was used for intra-group comparisons. P-value, comparison between Day 0 and Day 84 at the same group. Independent T-test and non-parametric K independent Wilcoxon signed-ranks was used for comparisons of the changes between the two groups. P, comparison of the fold changes between the CP group and the G group.CP group, cyclocarya paliurus leaves extracts group; G group, Glipizide group; SD, standard deviation; IQR, interquartile range; HbA1c, hemoglobin A1c; FBG, fasting blood glucose; 2hPBG, 2-hour post-meal blood glucose; FINS, fasting insulin; 2hPINS, 2-hour post-meal insulin; HOMA-IR, homeostasis model assessment for insulin resistance = (fasting blood glucose×fasting insulin/ 22.5); 2hPCP, 2-hour post-meal C-Peptide; OGTT, oral glucose tolerance test; AUC, area under curve; TG, triglycerides; TC, total cholesterol; LDL-c, low-density lipoprotin cholesterol; HDL-c, high-density lipoprotein cholesterol; BW, body weight; WC, waist circumference; WHR, waist to hip ratio; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; ALB, albumin;ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, serum creatinine; BUN, blood urea nitrogen.